Fuad Novruzov, Abstract Co-Author: Nothing to Disclose

James Patrick Connelly MBBS, Presenter: Nothing to Disclose

Jamil A Aliyev, Abstract Co-Author: Nothing to Disclose

Jamshed Bomanji, Abstract Co-Author: Nothing to Disclose

Ming Young Simon Wan MBBChir, Abstract Co-Author: Nothing to Disclose

Rizwan Syed MBBS, FRCR, Abstract Co-Author: Nothing to Disclose

Irfan Akbar Kayani MRCP, FRCR, Abstract Co-Author: Nothing to Disclose

68Ga-Dota-DPhe1, Tyr3-octreotate (68Ga-Dotatate) is a novel selective somatostatin analogue ligand which shows increased affinity for somatostatin receptor subtype 2 (SST2) and has been increasingly used for imaging neuroendocrine tumours with PET/CT. We investigated the utility of 68Ga-Dotatate positron emission tomography/computed tomography (PET/CT) in patients with benign and malignant insulinomas.  

We enrolled forty consecutive patients (17 men, 23 women), mean age of 47.3 (range: 8-83) who underwent 68Ga-Dotatate PET/CT on basis of a) suspected insulinoma (10/40), b) suspected recurrent insulinoma (15/40) and c) localisation of biochemically proven insulinoma (15/40). 68Ga-Dotatate PET/CT findings were correlated with final diagnosis and results of conventional imaging modalities (diagnostic CT and MRI).  

In 40 patients 68Ga-Dotatate PET/CT was true positive in 20, true negative in 13, false negative in 5 and false positive in two. Overall sensitivity, specificity, PPV and NPV 40 patients for 68Ga-Dotatate was 80%, 87%, 0.9 and 0.72. There was a significant difference (p=0.046) for detection of benign versus malignant insulinomas with 68Ga-Dotatate. The sensitivity, specificity, PPV and NPV of 68Ga-Dotatate for benign tumours was 64 %, 100 %, 1 and 0.5. The sensitivity, specificity, PPV and NPV of 68Ga-Dotatate for malignant tumours was 100%, 100%, 1, and 1. 68Ga-Dotatate PET/CT was able to localise insulinoma in 3 patients with false negative CT/MRI. In 1 patient insulinoma was positive with CT/MRI but false negative with 68Ga-Dotatate PET/CT. In 3 patients 68Ga-Dotatate PET/CT and CT/MRI were false negative for benign insulinomas.  

68Ga-Dotatate PET/CT is useful to determine the presence of insulinoma. 68Ga-Dotatate has a higher sensitivity in patients with malignant versus benign tumours. 

68Ga-Dotatate is a novel selective somatostatin analogue ligand which shows increased affinity for somatostatin receptor subtype 2 (SST2) and has been increasingly used for imaging neuroendocrine tumours with PET/CT.

Novruzov, F, Connelly, J, Aliyev, J, Bomanji, J, Wan, M, Syed, R, Kayani, I, The Use of Ga68-DOTATATE PET/CT for Diagnostic Assessment in Insulinomas  .  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14045759.html